Clara Dong, an analyst from Jefferies, maintained the Buy rating on Aldeyra Therapeutics. The associated price target is $7.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Clara Dong’s rating is based on several promising developments for Aldeyra Therapeutics. The FDA’s acceptance of the resubmitted NDA for Reproxalap in treating dry eye disease is a significant milestone, reducing regulatory risks after previous setbacks. The recent Phase 3 trial successfully met its primary endpoint, addressing prior concerns and paving the way for potential approval by December 16, 2025. This approval could also trigger a strategic option agreement with ABBV, potentially leading to substantial financial gains and a clear commercial pathway for Reproxalap.
Furthermore, Aldeyra Therapeutics is positioned as a platform story with multiple ongoing clinical programs, offering potential future cash flows. The company has received Orphan Drug Designation for its intravitreal methotrexate, ADX-2191, and is advancing other promising candidates like ADX-629 and ADX-248. These developments, combined with the potential for ABBV to leverage its marketing experience, particularly in ocular redness, provide a compelling case for a Buy rating on ALDX stock.